Foreign Investment In US Biotech Gets Greater Gov't Scrutiny

By Carl Valenstein, Stephen Mahinka and Beverly Dale (July 11, 2019, 1:17 PM EDT) -- In 2019, under the current administration, there is increasing scrutiny of foreign investment — particularly from China — in the U.S. biotech industry.[1] These efforts by the Trump administration began back in March 2018 with the publication of the Section 301 report by the United States Trade Representative.[2] Since then, the Committee on Foreign Investment in the United States has blocked or required mitigation in several transactions in the life sciences industry....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!